Emerging drugs and vaccines for Candidemia

Brad Moriyama, Lori A. Gordon, Matthew Mccarthy, Stacey A. Henning, Thomas J. Walsh, Scott R. Penzak

Research output: Contribution to journalArticle

Abstract

Candidemia and other forms of invasive candidiasis are important causes of morbidity and mortality. The evolving challenge of antimicrobial resistance among fungal pathogens continues to highlight the need for potent, new antifungal agents. MEDLINE, EMBASE, Scopus and Web of Science searches (up to January 2014) of the English-language literature were performed with the keywords 'Candida' or 'Candidemia' or 'Candidiasis' and terms describing investigational drugs with activity against Candida spp. Conference abstracts and the bibliographies of pertinent articles were also reviewed for relevant reports. ClinicalTrials.gov was searched for relevant clinical trials. Currently available antifungal agents for the treatment of candidemia are summarised. Investigational antifungal agents with potential activity against Candida bloodstream infections and other forms of invasive candidiasis and vaccines for prevention of Candida infections are also reviewed as are selected antifungal agents no longer in development. Antifungal agents currently in clinical trials include isavuconazole, albaconazole, SCY-078, VT-1161 and T-2307. Further data are needed to determine the role of these compounds in the treatment of candidemia and other forms of invasive candidiasis. The progressive reduction in antimicrobial drug development may result in a decline in antifungal drug discovery. Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life-threatening mycoses.

Original languageEnglish (US)
Pages (from-to)718-733
Number of pages16
JournalMycoses
Volume57
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Candidemia
Antifungal Agents
Invasive Candidiasis
Vaccines
Candida
Pharmaceutical Preparations
Clinical Trials
Investigational Drugs
Mycoses
Candidiasis
Bibliography
Drug Discovery
Infection
MEDLINE
Language
Morbidity
Mortality

Keywords

  • Candida
  • Antifungal agents
  • Candidemia
  • Investigational
  • Vaccines

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Moriyama, B., Gordon, L. A., Mccarthy, M., Henning, S. A., Walsh, T. J., & Penzak, S. R. (2014). Emerging drugs and vaccines for Candidemia. Mycoses, 57(12), 718-733. https://doi.org/10.1111/myc.12265

Emerging drugs and vaccines for Candidemia. / Moriyama, Brad; Gordon, Lori A.; Mccarthy, Matthew; Henning, Stacey A.; Walsh, Thomas J.; Penzak, Scott R.

In: Mycoses, Vol. 57, No. 12, 01.12.2014, p. 718-733.

Research output: Contribution to journalArticle

Moriyama, B, Gordon, LA, Mccarthy, M, Henning, SA, Walsh, TJ & Penzak, SR 2014, 'Emerging drugs and vaccines for Candidemia', Mycoses, vol. 57, no. 12, pp. 718-733. https://doi.org/10.1111/myc.12265
Moriyama B, Gordon LA, Mccarthy M, Henning SA, Walsh TJ, Penzak SR. Emerging drugs and vaccines for Candidemia. Mycoses. 2014 Dec 1;57(12):718-733. https://doi.org/10.1111/myc.12265
Moriyama, Brad ; Gordon, Lori A. ; Mccarthy, Matthew ; Henning, Stacey A. ; Walsh, Thomas J. ; Penzak, Scott R. / Emerging drugs and vaccines for Candidemia. In: Mycoses. 2014 ; Vol. 57, No. 12. pp. 718-733.
@article{94766deb408e44489e1baf1f5027879d,
title = "Emerging drugs and vaccines for Candidemia",
abstract = "Candidemia and other forms of invasive candidiasis are important causes of morbidity and mortality. The evolving challenge of antimicrobial resistance among fungal pathogens continues to highlight the need for potent, new antifungal agents. MEDLINE, EMBASE, Scopus and Web of Science searches (up to January 2014) of the English-language literature were performed with the keywords 'Candida' or 'Candidemia' or 'Candidiasis' and terms describing investigational drugs with activity against Candida spp. Conference abstracts and the bibliographies of pertinent articles were also reviewed for relevant reports. ClinicalTrials.gov was searched for relevant clinical trials. Currently available antifungal agents for the treatment of candidemia are summarised. Investigational antifungal agents with potential activity against Candida bloodstream infections and other forms of invasive candidiasis and vaccines for prevention of Candida infections are also reviewed as are selected antifungal agents no longer in development. Antifungal agents currently in clinical trials include isavuconazole, albaconazole, SCY-078, VT-1161 and T-2307. Further data are needed to determine the role of these compounds in the treatment of candidemia and other forms of invasive candidiasis. The progressive reduction in antimicrobial drug development may result in a decline in antifungal drug discovery. Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life-threatening mycoses.",
keywords = "Candida, Antifungal agents, Candidemia, Investigational, Vaccines",
author = "Brad Moriyama and Gordon, {Lori A.} and Matthew Mccarthy and Henning, {Stacey A.} and Walsh, {Thomas J.} and Penzak, {Scott R.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/myc.12265",
language = "English (US)",
volume = "57",
pages = "718--733",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Emerging drugs and vaccines for Candidemia

AU - Moriyama, Brad

AU - Gordon, Lori A.

AU - Mccarthy, Matthew

AU - Henning, Stacey A.

AU - Walsh, Thomas J.

AU - Penzak, Scott R.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Candidemia and other forms of invasive candidiasis are important causes of morbidity and mortality. The evolving challenge of antimicrobial resistance among fungal pathogens continues to highlight the need for potent, new antifungal agents. MEDLINE, EMBASE, Scopus and Web of Science searches (up to January 2014) of the English-language literature were performed with the keywords 'Candida' or 'Candidemia' or 'Candidiasis' and terms describing investigational drugs with activity against Candida spp. Conference abstracts and the bibliographies of pertinent articles were also reviewed for relevant reports. ClinicalTrials.gov was searched for relevant clinical trials. Currently available antifungal agents for the treatment of candidemia are summarised. Investigational antifungal agents with potential activity against Candida bloodstream infections and other forms of invasive candidiasis and vaccines for prevention of Candida infections are also reviewed as are selected antifungal agents no longer in development. Antifungal agents currently in clinical trials include isavuconazole, albaconazole, SCY-078, VT-1161 and T-2307. Further data are needed to determine the role of these compounds in the treatment of candidemia and other forms of invasive candidiasis. The progressive reduction in antimicrobial drug development may result in a decline in antifungal drug discovery. Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life-threatening mycoses.

AB - Candidemia and other forms of invasive candidiasis are important causes of morbidity and mortality. The evolving challenge of antimicrobial resistance among fungal pathogens continues to highlight the need for potent, new antifungal agents. MEDLINE, EMBASE, Scopus and Web of Science searches (up to January 2014) of the English-language literature were performed with the keywords 'Candida' or 'Candidemia' or 'Candidiasis' and terms describing investigational drugs with activity against Candida spp. Conference abstracts and the bibliographies of pertinent articles were also reviewed for relevant reports. ClinicalTrials.gov was searched for relevant clinical trials. Currently available antifungal agents for the treatment of candidemia are summarised. Investigational antifungal agents with potential activity against Candida bloodstream infections and other forms of invasive candidiasis and vaccines for prevention of Candida infections are also reviewed as are selected antifungal agents no longer in development. Antifungal agents currently in clinical trials include isavuconazole, albaconazole, SCY-078, VT-1161 and T-2307. Further data are needed to determine the role of these compounds in the treatment of candidemia and other forms of invasive candidiasis. The progressive reduction in antimicrobial drug development may result in a decline in antifungal drug discovery. Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life-threatening mycoses.

KW - Candida

KW - Antifungal agents

KW - Candidemia

KW - Investigational

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84912528864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912528864&partnerID=8YFLogxK

U2 - 10.1111/myc.12265

DO - 10.1111/myc.12265

M3 - Article

C2 - 25294098

AN - SCOPUS:84912528864

VL - 57

SP - 718

EP - 733

JO - Mycoses

JF - Mycoses

SN - 0933-7407

IS - 12

ER -